Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters in connection with the transaction. Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company, announced it has raised...
You must be a Standard 1 Year member to access this content.
Cooley, Travers Thorp Alberga and Jun He Law Offices advised ProfoundBio and Wilson Sonsini Goodrich and Rosati advised ProfoundBio on patent matters related to the transaction,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction, and Cooley represented the underwriters. Edgewise Therapeutics, Inc. (“Edgewise”) (NASDAQ: EWTX) announced the pricing of an underwritten...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised BigHat on the transaction. AbbVie Inc. and BigHat Biosciences announced a research collaboration to discover and develop next-generation therapeutic antibodies...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis LLP is representing L Catterton, and Wilson Sonsini Goodrich & Rosati is representing Thorne HealthTech, Inc. in the transaction. Thorne HealthTech, Inc. (“Thorne”)...
You must be a Standard 1 Year member to access this content.
Wilson, Sonsini is acting as legal counsel to Amphastar. Kirkland & Ellis and Covington & Burling are acting as legal counsel to Lilly. In an effort...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised EpiBiologics on the deal. EpiBiologics, a biotechnology company building a next-generation antibody-based protein degradation platform for membrane and extracellular drug targets, launched with...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised DICE Therapeutics on the deal. DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented client Section 32 on the deal while Wilson Sonsini advised BigHat Biosciences. Section 32, a venture capital fund that invests in frontiers of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Quanta Therapeutics on the deal. Quanta Therapeutics, Inc., a privately held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction. CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Fenwick & West advised DiCE Molecules on the deal. DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform...
You must be a Standard 1 Year member to access this content.
